MA43767A - Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer - Google Patents

Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer

Info

Publication number
MA43767A
MA43767A MA043767A MA43767A MA43767A MA 43767 A MA43767 A MA 43767A MA 043767 A MA043767 A MA 043767A MA 43767 A MA43767 A MA 43767A MA 43767 A MA43767 A MA 43767A
Authority
MA
Morocco
Prior art keywords
receptor
cancer
treatment
directed against
extracellular domain
Prior art date
Application number
MA043767A
Other languages
English (en)
Other versions
MA43767B1 (fr
Inventor
Caroline Mary
Nicolas Poirier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA43767A publication Critical patent/MA43767A/fr
Publication of MA43767B1 publication Critical patent/MA43767B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA43767A 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer MA43767B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (fr) 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et son utilisation dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA43767A true MA43767A (fr) 2019-01-09
MA43767B1 MA43767B1 (fr) 2019-08-30

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43767A MA43767B1 (fr) 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer

Country Status (22)

Country Link
US (1) US11230602B2 (fr)
EP (1) EP3423496B1 (fr)
JP (1) JP7053479B2 (fr)
KR (1) KR102819051B1 (fr)
CN (1) CN109195987B (fr)
AU (1) AU2017225495B2 (fr)
CY (1) CY1122072T1 (fr)
DK (1) DK3423496T3 (fr)
ES (1) ES2737307T3 (fr)
HR (1) HRP20191445T1 (fr)
HU (1) HUE045183T2 (fr)
IL (1) IL261330B2 (fr)
LT (1) LT3423496T (fr)
MA (1) MA43767B1 (fr)
MD (1) MD3423496T2 (fr)
ME (1) ME03446B (fr)
PL (1) PL3423496T3 (fr)
PT (1) PT3423496T (fr)
RS (1) RS59223B1 (fr)
SI (1) SI3423496T1 (fr)
SM (1) SMT201900460T1 (fr)
WO (1) WO2017149394A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
WO2019043065A1 (fr) * 2017-08-29 2019-03-07 Ose Immunotherapeutics Procédé et préparation permettant de trier des lymphocytes t effecteurs à l'aide d'anticorps anti-cd127 pour des applications en thérapie cellulaire
AU2019265888B2 (en) * 2018-05-10 2026-04-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
US20220273713A1 (en) * 2019-06-28 2022-09-01 The University Of Melbourne Method of inhibiting or activating gamma delta t cells
EP4065605A4 (fr) 2019-11-26 2023-07-12 Ramot at Tel-Aviv University Ltd. Anticorps dirigés contre des antigènes glucidiques
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
WO2021222227A1 (fr) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Récepteur antigénique chimérique ciblant cd127 et utilisation associée
AU2021275055A1 (en) * 2020-05-18 2023-02-02 Mouhannad Jumaa Composition for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ES2686593T3 (es) 2006-05-31 2018-10-18 The Regents Of The University Of California Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
EP1930342B1 (fr) 2006-12-04 2012-01-25 Institut Pasteur OB-fold utilisé en tant que base pour l'ingénierie de nouveaux liants spécifiques
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (fr) 2009-01-22 2010-07-29 University Of Miami Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7
PE20170687A1 (es) * 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2583980A1 (fr) 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127

Also Published As

Publication number Publication date
KR102819051B1 (ko) 2025-06-12
MA43767B1 (fr) 2019-08-30
PL3423496T3 (pl) 2020-01-31
IL261330A (en) 2018-10-31
LT3423496T (lt) 2019-09-25
HUE045183T2 (hu) 2019-12-30
EP3423496B1 (fr) 2019-07-03
JP2019515648A (ja) 2019-06-13
SI3423496T1 (sl) 2019-10-30
AU2017225495B2 (en) 2024-05-09
IL261330B (en) 2022-11-01
SMT201900460T1 (it) 2019-09-09
PT3423496T (pt) 2019-09-05
AU2017225495A1 (en) 2018-08-23
CN109195987B (zh) 2022-05-27
JP7053479B2 (ja) 2022-04-12
RS59223B1 (sr) 2019-10-31
BR112018067479A2 (pt) 2019-01-15
US11230602B2 (en) 2022-01-25
KR20180118746A (ko) 2018-10-31
MD3423496T2 (ro) 2020-01-31
HRP20191445T1 (hr) 2019-11-15
US20200308288A1 (en) 2020-10-01
DK3423496T3 (da) 2019-08-19
CN109195987A (zh) 2019-01-11
ME03446B (fr) 2020-01-20
CY1122072T1 (el) 2020-11-25
CA3014313A1 (fr) 2017-09-08
EP3423496A1 (fr) 2019-01-09
IL261330B2 (en) 2023-03-01
ES2737307T3 (es) 2020-01-13
WO2017149394A1 (fr) 2017-09-08

Similar Documents

Publication Publication Date Title
MA43767A (fr) Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer
IL279752A (en) Polycyclic compounds and use thereof in the treatment of immune disorders
IL265217A (en) Glucocorticoid receptor modulators to treat pancreatic cancer
EP3731868A4 (fr) Anticorps anti-tigit et leur utilisation comme agents thérapeutiques et diagnostiques
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
EP3400013A4 (fr) Anticorps spécifiques pour la cadhérine-17 et cellules cytotoxiques pour le traitement du cancer
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
EP2814509A4 (fr) Anticorps dirigés contre l'intégrine v 6 et leur utilisation pour le traitement du cancer
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
CY1126258T1 (el) Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων
EP3302558A4 (fr) Agents anticancéreux et procédés d'utilisation
ME03078B (fr) Dérivés de sulfonylpipéridine et leur utilisation pour le traitement de maladies médiées par une prokinéticine
EP3328401A4 (fr) Protéine 2 contenant le domaine de sperme motile et cancer
MA46085A (fr) Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires
EP2604276A4 (fr) Utilisation d'anticorps dirigés contre les récepteurs nk1, nk2 et/ou nk3, dans le traitement du cancer
EP2702992A4 (fr) Utilisation de mélatonine pour le traitement et/ou la prévention de la mucosite
FR2999428B1 (fr) Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
PL3678692T3 (pl) Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
EP3645019A4 (fr) Compositions et méthodes pour thérapie cellulaire adoptive
EP3283528A4 (fr) Anticorps humain anti-vegfr2 pour traitement anti-angiogénique et anticancéreux ciblé
EP3363461A4 (fr) Anticorps anti-cd43 et leur utilisation pour le traitement du cancer